keyword
MENU ▼
Read by QxMD icon Read
search

Myeloma,velcade,revlimid,

keyword
https://www.readbyqxmd.com/read/27441522/diarrhea-in-multiple-myeloma-a-review-of-the-literature
#1
Beth Faiman
BACKGROUND: One of the most common and inadequately managed symptoms that patients with multiple myeloma (MM) experience as a result of cancer treatment is diarrhea. Diarrhea in patients with MM often is severe enough to warrant dose reduction, delays, or discontinuation of chemotherapy. Short-term diarrhea can occur as a side effect of drugs, such as bortezomib (Velcade®) or panobinostat (Farydak®). Late-onset diarrhea from lenalidomide (Revlimid®) can occur 17-24 months after the start of therapy...
August 1, 2016: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/26321720/-a-newly-diagnosed-case-of-multiple-myeloma-in-which-lenalidomide-was-continued-after-surgery-for-a-pancreatic-neuroendocrine-tumor-that-developed-during-lenalidomide-maintenance-therapy
#2
Hiroyuki Kuroda, Masahiro Yoshida, Makoto Usami, Saori Shimoyama, Hiroki Sakamoto, Michiko Yamada, Shigeyuki Fujii, Masahiro Maeda, Miri Fujita, Yusuke Kanari, Tsutomu Sato, Junji Kato
A 75-year-old woman was diagnosed with symptomatic IgG-l multiple myeloma (good-prognosis group) in December 2010. A stringent complete response (sCR) was achieved by using induction therapy with bortezomib (BOR, Velcade®)+ dexamethasone (DEX)(VD) and consolidation therapy with BOR+lenalidomide (LEN, Revlimid®)+DEX(VRD). Although maintenance therapy with Revlimid®+DEX(Rd) was initiated, a pancreatic neuroendocrine tumor was detected in April 2013. Therefore, LEN was discontinued and distal pancreatectomy was performed in September 2013...
August 2015: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/25342294/severe-resistant-hypocalcemia-in-multiple-myeloma-after-zoledronic-acid-administration-a-case-report
#3
Adrian P Noriega Aldave, Shikha Jaiswal
INTRODUCTION: Hypercalcemia is one of the most common metabolic abnormalities encountered in any form of malignancy. Hypocalcemia, however, is a rare manifestation, especially in cancers with bone involvement. Here we present a case of hypocalcemia in a patient with multiple myeloma that was refractory to treatment. CASE PRESENTATION: A 73-year-old African American woman recently diagnosed with multiple myeloma, presented with a 2-day history of fever, vomiting and hypocalcemia...
October 23, 2014: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/25188481/treatment-related-adverse-events-in-patients-with-relapsed-refractory-multiple-myeloma
#4
REVIEW
Ravi Vij
In the past decade we have seen four new agents approved by the US Food and Drug Administration for treatment of multiple myeloma: the proteasome inhibitor (PI) bortezomib (Velcade), the immunomodulatory agents lenalidomide (Revlimid) and thalidomide (Thalomid), and liposomal doxorubicin. These are commonly used in the treatment of relapsed/refractory (R/R) multiple myeloma (MM), but there is no universally accepted standard treatment. Salvage therapy must be tailored according to an individual patient's clinical profile, with the risks and potential effects of treatment-related adverse events being major determinants of the choice of therapy...
November 15, 2011: Oncology (Williston Park, NY)
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"